Retatrutide
5mg/vial
Triple receptor agonist (GLP-1, GIP, Glucagon) — 5mg entry-level vial for dose-titration research.
Choose dosage
Price per vial
$89.99
5mg/vial
Concentration
5mg/vial
Warehouse
US Domestic
Product Description
Retatrutide is a novel triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. This 5mg vial is designed for titration-phase research protocols requiring smaller starting doses.
Research Overview
The 5mg vial format supports early-phase dose escalation research where incremental receptor engagement is studied across the three target pathways. The glucagon receptor component provides hepatic glucose modulation not present in dual GLP-1/GIP analogues. Suitable for establishing dose-response baselines before progressing to higher-concentration vials. For in-vitro and laboratory research use only.
Research Applications
Certificate of Analysis (Janoshik)
Research Use Only
This product is intended solely for laboratory research and analytical purposes. Not for human consumption or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA.